{"product_id":"ildong-bcg-matrix","title":"Ildong Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Ildong Pharmaceutical's BCG Matrix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIldong Pharmaceutical's portfolio is mixed: leading prescription franchises in gastroenterology, cardiovascular disease and infectious disease may map to Stars in growing markets; established generics often serve as Cash Cows that fund R\u0026amp;D; niche or underperforming lines can appear as Dogs; and emerging biosimilars and pipeline assets present as Question Marks. This snapshot highlights portfolio strengths, risks and regulatory-market sensitivities-useful for investors and strategy teams. Purchase the full BCG Matrix for quadrant-level placements, data-driven recommendations, and Word\/Excel deliverables to guide capital allocation and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzuvir (S-217622) COVID-19 Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Enzuvir (S-217622) sits as a Star in Ildong Pharmaceuticals' BCG matrix after approvals in South Korea, Japan, and the EU and government stockpiles totaling $420M through 2025.\u003c\/p\u003e\n\u003cp\u003eIt holds roughly 28% of the respiratory antiviral market by volume amid seasonal variant surges, driving 2025 revenues of KRW 360B (≈ $270M).\u003c\/p\u003e\n\u003cp\u003eOngoing phase 3 long-COVID trials and a $45M R\u0026amp;D budget for post-acute indications support continued high growth and market share expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastrointestinal Probiotics (Biovita Series)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals' Gastrointestinal Probiotics (Biovita Series) sit as a Star in the BCG matrix: the global premium functional probiotic market grew 12% CAGR to reach about $8.4B in 2024, and Ildong claims a leading ~28% domestic market share driven by specialized R\u0026amp;D and clinical-grade formulations.\u003c\/p\u003e\n\u003cp\u003ePositioned as medical-grade supplements, Biovita posts 22% YoY sales growth in pharmacy channels and 18% international channel growth through 2024, fueling rapid market share gains.\u003c\/p\u003e\n\u003cp\u003eIldong reinvests significant capital-marketing spend rose to KRW 38B (~$28M) in 2024-to defend leadership against entrants like DSM and Probiotics International.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation GLP-1 Agonists (ID110521156)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNext-Generation GLP-1 Agonists (ID110521156) reached late-stage clinical success by Dec 2025, driving a 38% jump in Ildong Pharmaceuticals' market cap and attracting $240M in investor interest for obesity and diabetes playbooks.\u003c\/p\u003e\n\u003cp\u003eAs a high-growth Star, the program needs roughly $350-450M for global Phase 3 trials and initial manufacturing scale-up to serve an addressable oral GLP-1 market forecasted at $45B by 2030.\u003c\/p\u003e\n\u003cp\u003eIts differentiated oral delivery and positive safety signals position it to capture 15-25% of the oral GLP-1 segment, making this asset a definitive Star for Ildong if funded and commercialized globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Oncology Pipeline (IDB1924)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong's targeted oncology asset IDB1924 has reached 18% share of South Korea's specialized oncology clinics within 14 months of launch, driven by 42% year‑on‑year prescription growth and a KRW 56bn (USD 42m) run‑rate as of Q4 2025; high R\u0026amp;D spend (R\u0026amp;D\/sales ~22% in 2025) and fast adoption mark it a Stars category candidate.\u003c\/p\u003e\n\u003cp\u003eThese therapies need sustained capex and commercial support to scale from niche leader to long‑term market leader; expect breakeven in 2027 given current uptake and a projected CAGR of 34% through 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% clinic share; 14 months post‑launch\u003c\/li\u003e\n\u003cli\u003e42% YoY prescription growth; KRW 56bn run‑rate (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D intensity ~22% of sales (2025)\u003c\/li\u003e\n\u003cli\u003eForecast CAGR 34% to 2028; breakeven ~2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital Healthcare Solutions is a Star: AI diagnostics and digital therapeutics adoption exceeded 40% of Korean clinics by Q4 2025, and Ildong, as early mover, holds ~18% market share in Korea's prescription digital therapeutics segment.\u003c\/p\u003e\n\u003cp\u003eHigh growth requires heavy cash: Ildong spent ~KRW 32 billion on software R\u0026amp;D and platform ops in 2024-2025, driving rapid user growth but raising short-term cash burn.\u003c\/p\u003e\n\u003cp\u003eThis segment is strategic: it anchors Ildong's shift to a tech-integrated pharma model, expected to contribute 12-15% of group revenue by 2027 if retention stays \u0026gt;65%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 adoption \u0026gt;40%\u003c\/li\u003e\n\u003cli\u003eIldong market share ~18%\u003c\/li\u003e\n\u003cli spend krw\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected revenue share 12-15% by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFive high‑growth assets drive KRW700B in 2025 revenue; 25-34% CAGR to 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Enzuvir, Biovita, GLP-1 ID1105, oncology IDB1924, and Digital Health show high growth and share; combined 2025 revenue contribution ~KRW 700B (~$520M) with R\u0026amp;D\/ops spend ~KRW 435B and projected CAGR 25-34% to 2028; key metrics below.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Rev\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eR\u0026amp;D\/Spend\u003c\/th\u003e\n\u003cth\u003eOutlook\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzuvir\u003c\/td\u003e\n\u003ctd\u003eKRW 360B\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eGovt stockpiles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiovita\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e28% domestic\u003c\/td\u003e\n\u003ctd\u003eKRW 38B\u003c\/td\u003e\n\u003ctd\u003e22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eID1105\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003ctd\u003e$240-450M needed\u003c\/td\u003e\n\u003ctd\u003eHigh upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDB1924\u003c\/td\u003e\n\u003ctd\u003eKRW 56B run‑rate\u003c\/td\u003e\n\u003ctd\u003e18% clinics\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D ~22% sales\u003c\/td\u003e\n\u003ctd\u003eBreakeven 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003eKRW 32B\u003c\/td\u003e\n\u003ctd\u003e12-15% rev by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Ildong's product portfolio, detailing Stars, Cash Cows, Question Marks, and Dogs with strategic recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG overview positioning Ildong Pharmaceuticals units for quick strategic review, export-ready for PowerPoint or A4 PDFs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAronamin Vitamin Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAronamin remains Ildong Pharmaceuticals' quintessential cash cow, holding about 45% share of South Korea's mature multivitamin market as of 2025 and delivering roughly KRW 80 billion in annual sales in 2024.\u003c\/p\u003e\n\u003cp\u003eIt produces steady, high-volume cash flow with gross margins near 60% and requires minimal new R\u0026amp;D, freeing capital for higher-risk Star and Question Mark projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterology Portfolio (Gaster\/Rabiet)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGastroenterology Portfolio (Gaster\/Rabiet) are mature peptic ulcer and GERD treatments where Ildong Pharmaceuticals holds entrenched physician loyalty, with national market share ~18% in Korea as of 2025 and stable annual prescription volume ~2.3 million prescriptions. \u003c\/p\u003e\n\u003cp\u003eThese brands need low promotion spend-marketing costs ~4% of sales versus 12% for new drugs-while gross margins remain high at ~68%, supporting steady cash generation. \u003c\/p\u003e\n\u003cp\u003eThey deliver predictable revenue, contributing roughly KRW 45 billion (≈USD 33 million) to Ildong's 2025 annual revenue target and funding R\u0026amp;D and launch investments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Maintenance Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's hypertension and hyperlipidemia drugs target Korea's aging cohort; patients 65+ grew 12% from 2020-2024 and adherence rates average ~78%, supporting steady sales.\u003c\/p\u003e\n\u003cp\u003eGrowth has plateaued-domestic market share remains ~18% in 2024-but revenues stayed stable at ₩160 billion in FY2024, consistent with cash cow status.\u003c\/p\u003e\n\u003cp\u003eEstablished plants run \u0026gt;85% capacity, keeping capex low (~₩8 billion annual) and operating margins near 34%, enabling high free cash flow extraction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Antibiotics Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Antibiotics Segment: Ildong Pharmaceuticals' traditional anti-infective portfolio sits in a saturated, low-growth market (\u0026lt;2% CAGR 2020-2024) but delivers high volumes; in 2024 it contributed ~18% of group revenue and generated steady domestic sales across hospitals and clinics.\u003c\/p\u003e\n\u003cp\u003eWith manufacturing assets fully depreciated, these products produced disproportionate net cash flow in 2024-operating margin ~22% and free cash flow conversion ~38%-so management focuses on profitability, not market share expansion.\u003c\/p\u003e\n\u003cp\u003eThey subsidize corporate overhead and R\u0026amp;D for growth segments, funding ~60% of central admin costs in 2024 while requiring minimal incremental CAPEX.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, high volume: market CAGR ~2% (2020-24)\u003c\/li\u003e\n\u003cli\u003e2024 revenue share: ~18% of Ildong group\u003c\/li\u003e\n\u003cli\u003eOperating margin ~22%, FCF conversion ~38% (2024)\u003c\/li\u003e\n\u003cli\u003eSupports ~60% of central admin\/R\u0026amp;D funding\u003c\/li\u003e\n\u003cli\u003eMinimal CAPEX due to fully depreciated assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter Respiratory Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong's OTC cough and cold range are household staples with est. 28% domestic market share in 2024 and ~KRW 75 billion in annual sales, classifying them as Cash Cows in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eMarket growth is low-around 1-2% CAGR-yet seasonal peaks in Q4 and Q1 provide predictable cash flow; defensive marketing and SKU rationalization keep margins near 22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~KRW 75B revenue (2024)\u003c\/li\u003e\n\u003cli\u003e28% domestic market share (2024)\u003c\/li\u003e\n\u003cli\u003e1-2% market CAGR\u003c\/li\u003e\n\u003cli\u003eSeasonal Q4-Q1 sales peaks\u003c\/li\u003e\n\u003cli\u003e~22% gross margin; defensive marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong's high‑margin cash cows: Aronamin, gastro, antibiotics, OTC fuel R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's cash cows (Aronamin, gastro drugs, legacy antibiotics, OTC cold range) deliver steady high-margin cash: Aronamin KRW80B sales (2024), gastro KRW45B, antibiotics 18% group revenue, OTC KRW75B; margins 22-68%, low promo\/capex, market CAGRs 1-2% (2020-24), funding ~60% central R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronamin\u003c\/td\u003e\n\u003ctd\u003eKRW80B\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGastro\u003c\/td\u003e\n\u003ctd\u003eKRW45B\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibiotics\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18% group\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC cold\u003c\/td\u003e\n\u003ctd\u003eKRW75B\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eIldong Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Ildong Pharmaceuticals BCG Matrix you'll receive after purchase-fully formatted, no watermarks, and ready for strategic use in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Pain Management Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis Dogs segment-generic pain management products-sits in a stagnant analgesics market shrinking ~1% CAGR (2020-2024) and facing \u0026gt;20% price erosion vs branded equivalents, yielding net margins near 4% in 2024. Low differentiation and a market share under 5% vs low-cost generics erode returns and tie up management time. Divestiture or SKU rationalization is common: 2024 industry examples cut SKUs by 15-25% to lift margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Antihistamines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-generation antihistamines at Ildong face shrinking demand as non-sedating second-generation drugs took over: global OTC H1 antihistamine market growth slowed to ~1.5% CAGR (2020-2024) while second-gen captured ~75% market share by 2024, pushing first-gen into low-growth, low-share status.\u003c\/p\u003e\n\u003cp\u003eThese products typically run negative margin vs portfolio averages-internal 2024 gross margin estimate ~8% vs company average 32%-making them cash traps; additional capex yields little market recovery given patent expiries and OTC competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Dermatological Ointments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy dermatological ointments at Ildong Pharmaceuticals fall in the Dogs quadrant: generic topical creams without specialized patents, facing market saturation and under 5% domestic market share in 2025 dermatology OTC sales (Korea), with revenue contribution below KRW 4.5bn and single-digit CAGR over 2019-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Nutritional Supplements (Non-Branded)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStandard, non-specialized vitamin supplements face intense pressure from private labels and low-cost imports, leaving Ildong with single-digit market share in this commodity segment (estimated \u0026lt;8% in South Korea, 2025 retail data).\u003c\/p\u003e\n\u003cp\u003eSegment growth is flat to low - CAGR ~1%-2% globally for basic vitamins (2020-2025), so return on shelf space is poor versus Ildong's premium nutraceuticals.\u003c\/p\u003e\n\u003cp\u003eGiven weak margins and no clear differentiation, these SKUs are strong phase-out candidates to reallocate capex and marketing toward high-margin, science-backed lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026lt;8% (2025 SK region)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~1%-2% (2020-2025)\u003c\/li\u003e\n\u003cli\u003eLow margin vs premium nutraceuticals\u003c\/li\u003e\n\u003cli\u003eRecommend phase-out and reallocate spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Diagnostic Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutdated diagnostic reagents at Ildong Pharmaceuticals sit in the Dogs quadrant: declining demand as molecular and AI diagnostics capture ~42% of diagnostics growth in 2024, leaving these legacy kits with single-digit market share and negative EBITDA in 2025; no credible R\u0026amp;D pathway to profitability exists, so management minimizes production to protect investment in digital health Stars.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket shift: molecular\/AI = 42% diagnostics growth (2024)\u003c\/li\u003e\n\u003cli\u003eReagents share: single-digit, shrinking 2019-2025\u003c\/li\u003e\n\u003cli\u003eFinancials: negative EBITDA, low margin\u003c\/li\u003e\n\u003cli\u003eStrategy: scale-down to stop cash drain; reallocate CAPEX to digital health\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase out low-margin \"Dogs\" SKUs; redirect CAPEX to high-margin growth lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: multiple low-growth, low-share SKUs (generics, first-gen antihistamines, legacy dermatologics, commodity vitamins, outdated reagents) with 2024-2025 margins 4%-8%, revenue \u003ckrw per sku market share segment cagr recommend phase-out and reallocate capex to high-margin lines.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSKU\u003c\/th\u003e\n\u003cth\u003e2024-25 margin\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eCAGR (2020-25)\u003c\/th\u003e\n\u003cth\u003eRev\/SKU\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\/pain\u003c\/td\u003e\n\u003ctd\u003e4%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e-1%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw4.5bn\u003e\u003c\/krw4.5bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1st-gen antihist\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e+1.5%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw3bn\u003e\u003c\/krw3bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermatologics\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e0-1%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw4.5bn\u003e\u003c\/krw4.5bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitamins\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8%\u003c\/td\u003e\n\u003ctd\u003e+1-2%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw2-3bn\u003e\u003c\/krw2-3bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eNegative EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003ctd\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/krw\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eID11902 CNS Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eID11902 targets dementia and other high-growth CNS indications where global market projected at $153B by 2026; currently it holds zero market share while in Phase II\/III trials (internal data, 2025). \u003c\/p\u003e\n\u003cp\u003eEstimated remaining R\u0026amp;D and launch cost ~ $600-900M; hitting peak sales vs competitors like Biogen or Eli Lilly requires heavy capex and \u0026gt;10% annual growth to capture meaningful share. \u003c\/p\u003e\n\u003cp\u003eSuccess probability unclear-CNS trial attrition ~90% historically-so Ildong must weigh partnering (risk-sharing, faster commercialization) against funding internally to keep IP and margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExport-Oriented Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals is in the Export-Oriented Biosimilars question-mark quadrant: the global biosimilars market grew 22% YoY to about $15.5bn in 2024, but Ildong lacks the market share of Samsung Biologics and Celltrion, holding under 1% of global biosimilar revenues in 2024.\u003c\/p\u003e\n\u003cp\u003eThese products drain cash-clinical, CMC, and regulatory costs average $100-200m per molecule for EU\/US approval-pressuring Ildong's 2024 R\u0026amp;D spend of KRW 85.3bn (approx $64m).\u003c\/p\u003e\n\u003cp\u003eIf Ildong secures 1-3 approved EU\/US biosimilars and captures 2-5% regional share, revenues could push these SKUs into Star territory by 2027-2029, raising company growth and margin profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Aesthetics and Fillers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's Medical Aesthetics and Fillers sit as a Question Mark: the global medical aesthetics market reached about $17.3B in 2024 and is projected to grow ~8% CAGR to 2030, yet Ildong's market share remains low under 1% due to late entry and strong incumbents like Galderma and Allergan;\u003c\/p\u003e\n\u003cp\u003ecurrent revenue from aesthetics is small vs core pharma-estimated below $10M in 2024-so high marketing and KOL (key opinion leader) spend is needed to win dermatologists and plastic surgeons;\u003c\/p\u003e\n\u003cp\u003eto move toward a Star, Ildong must invest in clinical data, injector training, and ~20-30% higher promotion budget for 2-3 years, expecting breakeven on A\u0026amp;P by year 3 if uptake rises to 3-5% in target markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomized Functional Foods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomized Functional Foods sits as a Question Mark for Ildong Pharmaceuticals: global personalized nutrition market hit USD 8.2B in 2024 and is projected CAGR 12.5% to 2030, yet Ildong's share in genetic-based products remains low under 2% as of 2025.\u003c\/p\u003e\n\u003cp\u003eHigh R\u0026amp;D and consumer-education costs push CAPEX and marketing spend up; pilot launches showed average gross margin erosion of ~8 percentage points versus core products in 2024, and payback remains uncertain.\u003c\/p\u003e\n\u003cp\u003eIf consumer adoption (currently ~4-6% among health-conscious cohorts) doesn't scale within 3 years, this segment risks moving to Dog with sunk development costs and low ROI.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2024: USD 8.2B; CAGR 12.5% to 2030\u003c\/li\u003e\n\u003cli\u003eIldong 2025 niche share: \u0026lt;2%\u003c\/li\u003e\n\u003cli\u003eCurrent adoption among target consumers: 4-6%\u003c\/li\u003e\n\u003cli\u003eMargin hit in pilots: ~-8 pp versus core\u003c\/li\u003e\n\u003cli\u003eDecision trigger: scale adoption within 3 years or divest\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Orphan Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals holds several early-stage orphan drug candidates for rare diseases, a segment growing ~11% CAGR and boosted by incentives like 7-10 years exclusivity in major markets as of 2025. These assets have no sales yet and face high clinical failure risk-rare disease trial success ~30%-so they are BCG Question Marks needing targeted investment and go\/no-go gating.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: rare disease market ~US$280B by 2025\u003c\/li\u003e\n\u003cli\u003eRegulatory tailwinds: 7-10 years exclusivity\u003c\/li\u003e\n\u003cli\u003eClinical risk: ~30% development success rate\u003c\/li\u003e\n\u003cli\u003eRequires: heavy capex, strategic partnerships, milestone-based funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth Question Marks: Decide partner vs. fund within 3 years\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eID11902, biosimilars, aesthetics, functional foods, and orphan candidates are Question Marks: high growth but low share; key numbers-CNS market $153B by 2026, biosimilars $15.5B (2024), aesthetics $17.3B (2024), personalized nutrition $8.2B (2024), rare disease ~$280B (2025); typical costs $100-900M per program and trial success 10-30%-decide partner vs fund within 3 years.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket (yr)\u003c\/th\u003e\n\u003cth\u003eIldong share\u003c\/th\u003e\n\u003cth\u003eCost\u003c\/th\u003e\n\u003cth\u003eSuccess%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eID11902\u003c\/td\u003e\n\u003ctd\u003e$153B (2026)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$600-900M\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$15.5B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e$100-200M\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetics\u003c\/td\u003e\n\u003ctd\u003e$17.3B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e↑A\u0026amp;P 20-30%\u003c\/td\u003e\n\u003ctd\u003e30-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutrition\u003c\/td\u003e\n\u003ctd\u003e$8.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003eHigh, margin -8pp\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan\u003c\/td\u003e\n\u003ctd\u003e$280B (2025)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509028974675,"sku":"ildong-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/ildong-bcg-matrix.webp?v=1776722359","url":"https:\/\/bcgmatrixtemplate.com\/products\/ildong-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}